Your browser doesn't support javascript.
loading
Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates, Jamie; Vijayakumar, Archana; Ghoshal, Sarani; Marchand, Bruno; Yi, Saili; Kornyeyev, Dmytro; Zagorska, Anna; Hollenback, David; Walker, Katie; Liu, Kathy; Pendem, Swetha; Newstrom, David; Brockett, Robert; Mikaelian, Igor; Kusam, Saritha; Ramirez, Ricardo; Lopez, David; Li, Li; Fuchs, Bryan C; Breckenridge, David G.
Afiliação
  • Bates J; Gilead Sciences, Foster City, CA, USA. Electronic address: jamie.bates@gilead.com.
  • Vijayakumar A; Gilead Sciences, Foster City, CA, USA.
  • Ghoshal S; Massachusetts General Hospital, Boston, MA, USA; Synlogic Therapeutics, Cambridge, MA, USA.
  • Marchand B; Gilead Sciences, Foster City, CA, USA.
  • Yi S; Gilead Sciences, Foster City, CA, USA.
  • Kornyeyev D; Gilead Sciences, Foster City, CA, USA.
  • Zagorska A; Gilead Sciences, Foster City, CA, USA.
  • Hollenback D; Gilead Sciences, Foster City, CA, USA.
  • Walker K; Gilead Sciences, Foster City, CA, USA.
  • Liu K; Gilead Sciences, Foster City, CA, USA.
  • Pendem S; Gilead Sciences, Foster City, CA, USA.
  • Newstrom D; Gilead Sciences, Foster City, CA, USA; Advanced Cell Diagnostics (ACD), Newark, CA, USA.
  • Brockett R; Gilead Sciences, Foster City, CA, USA; Visiopharm, Westminster, CO, USA.
  • Mikaelian I; Gilead Sciences, Foster City, CA, USA; 23andMe, San Mateo, CA, USA.
  • Kusam S; Gilead Sciences, Foster City, CA, USA.
  • Ramirez R; Gilead Sciences, Foster City, CA, USA.
  • Lopez D; Gilead Sciences, Foster City, CA, USA.
  • Li L; Gilead Sciences, Foster City, CA, USA.
  • Fuchs BC; Massachusetts General Hospital, Boston, MA, USA; Ferring Pharmaceuticals, San Diego, CA, USA.
  • Breckenridge DG; Gilead Sciences, Foster City, CA, USA.
J Hepatol ; 73(4): 896-905, 2020 10.
Article em En | MEDLINE | ID: mdl-32376414
ABSTRACT
BACKGROUND &

AIMS:

Non-alcoholic steatohepatitis (NASH) is a chronic liver disease characterized by hepatic lipid accumulation, inflammation, and progressive fibrosis. Acetyl-CoA carboxylase (ACC) catalyzes the rate-limiting step of de novo lipogenesis and regulates fatty acid ß-oxidation in hepatocytes. ACC inhibition reduces hepatic fat content and markers of liver injury in patients with NASH; however, the effect of ACC inhibition on liver fibrosis has not been reported.

METHODS:

A direct role for ACC in fibrosis was evaluated by measuring de novo lipogenesis, procollagen production, gene expression, glycolysis, and mitochondrial respiration in hepatic stellate cells (HSCs) in the absence or presence of small molecule inhibitors of ACC. ACC inhibitors were evaluated in rodent models of liver fibrosis induced by diet or the hepatotoxin, diethylnitrosamine. Fibrosis and hepatic steatosis were evaluated by histological and biochemical assessments.

RESULTS:

Inhibition of ACC reduced the activation of TGF-ß-stimulated HSCs, as measured by both α-SMA expression and collagen production. ACC inhibition prevented a metabolic switch necessary for induction of glycolysis and oxidative phosphorylation during HSC activation. While the molecular mechanism by which inhibition of de novo lipogenesis blocks glycolysis and oxidative phosphorylation is unknown, we definitively show that HSCs require de novo lipogenesis for activation. Consistent with this direct antifibrotic mechanism in HSCs, ACC inhibition reduced liver fibrosis in a rat choline-deficient, high-fat diet model and in response to chronic diethylnitrosamine-induced liver injury (in the absence of hepatic lipid accumulation).

CONCLUSIONS:

In addition to reducing lipid accumulation in hepatocytes, ACC inhibition also directly impairs the profibrogenic activity of HSCs. Thus, small molecule inhibitors of ACC may lessen fibrosis by reducing lipotoxicity in hepatocytes and by preventing HSC activation, providing a mechanistic rationale for the treatment of patients with advanced liver fibrosis due to NASH. LAY

SUMMARY:

Hepatic fibrosis is the most important predictor of liver-related outcomes in patients with non-alcoholic steatohepatitis (NASH). Small molecule inhibitors of acetyl-CoA carboxylase (ACC) reduce hepatic fat content and markers of liver injury in patients with NASH. Herein, we report that inhibition of ACC and de novo lipogenesis also directly suppress the activation of hepatic stellate cells - the primary cell responsible for generating fibrotic scar in the liver - and thus fibrosis. These data provide further evidence for the use of ACC inhibitors to treat patients with NASH and advanced fibrosis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acetil-CoA Carboxilase / Lipogênese / Células Estreladas do Fígado / Hepatopatia Gordurosa não Alcoólica / Fígado / Cirrose Hepática Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: J Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acetil-CoA Carboxilase / Lipogênese / Células Estreladas do Fígado / Hepatopatia Gordurosa não Alcoólica / Fígado / Cirrose Hepática Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: J Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2020 Tipo de documento: Article